Käsmann Lukas, Bolm Louisa, Janssen Stefan, Rades Dirk
Department of Radiation Oncology, University of Lübeck, Lübeck, Germany
Department of Radiation Oncology, University of Lübeck, Lübeck, Germany.
Anticancer Res. 2017 Mar;37(3):1535-1537. doi: 10.21873/anticanres.11482.
BACKGROUND/AIM: Only 0.1-0.17% of all lung cancer patients are diagnosed with stage I or II small cell lung cancer (SCLC). Radiochemotherapy remains the standard treatment for limited stage disease. This study focused on prognostic factors in early stage SCLC treated with radiochemotherapy.
Seven factors in eight patients with early stage SCLC were analyzed concerning the impact on overall survival, namely gender, age, Karnofsky performance score, N-category, UICC-stage, concurrent chemotherapy and prophylactic cranial irradiation (PCI).
Median overall survival was 46 months. On univariate analysis, UICC stage I (48 vs. 24 months, p=0.022) and PCI (48 vs. 20 months, p=0.004) were significantly associated with improved overall survival. On multivariate analysis, PCI was an independent positive prognostic factor (p<0.001).
UICC stage and PCI were identified as significant predictors of survival in early stage SCLC. PCI qualified as an independent positive prognostic factor and should be administered in early-stage SCLC.
背景/目的：在所有肺癌患者中，仅0.1 - 0.17%被诊断为Ⅰ期或Ⅱ期小细胞肺癌（SCLC）。放化疗仍然是局限期疾病的标准治疗方法。本研究聚焦于接受放化疗的早期SCLC的预后因素。
分析了8例早期SCLC患者的7个因素对总生存期的影响，这些因素分别为性别、年龄、卡诺夫斯基体能状态评分、N分期、国际抗癌联盟（UICC）分期、同步化疗及预防性颅脑照射（PCI）。
中位总生存期为46个月。单因素分析显示，UICCⅠ期（48个月对24个月，p = 0.022）和PCI（48个月对20个月，p = 0.004）与总生存期改善显著相关。多因素分析表明，PCI是独立的阳性预后因素（p < 0.001）。
UICC分期和PCI被确定为早期SCLC生存的重要预测因素。PCI符合独立阳性预后因素的标准，应在早期SCLC中应用。
